KEIO RESEARCHERS INFORMATION SYSTEM

Profile Summary 【 Display / hide 】

Profile Summary 【 Display / hide 】

Career 【 Display / hide 】

Career 【 Display / hide 】

• 2023.04

  -

  2025.03

  Yokohama General Hospital, Pharmacy department, pharmacist

• 2025.04

  -

  Present

  Keio University Faculty of Pharmacy, Division of Pharmacodynamics, Assistant Professor

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 2012.04

  -

  2019.03

  Keio University, Faculty of Pharmacy, Pharmaceutical department

  University, Graduated

• 2019.04

  -

  2023.03

  Keio university graduate school

  Graduate School, Graduated, Doctoral course

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• Ph.D. in Pharmaceutical Science, Keio university graduate school, Coursework, 2023.03

  β-ラクタム薬/β-ラクタマーゼ阻害薬の併用療法におけるin vivo pharmacokinetics/pharmacodynamics評価方法の構築

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• Pharmacist License, 2019.05

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Comparison of area under the concentration–time curve estimations between Practical Antimicrobial Therapeutic Drug Monitoring (PAT) versions 3 and 4 for vancomycin using two-point sampling

  Suzuki A., Fujihara H., Yamaguchi F., Yoshida H., Tanaka H., Ishigo T., Fujii S., Ebihara F., Maruyama T., Yagi Y., Hamada Y., Nagumo F., Samura M., Komatsu T., Tomizawa A., Chiba H., Takuma A., Nishi Y., Igarashi Y., Enoki Y., Matsumoto K.

  Journal of Infection and Chemotherapy 32 ( 7 )  2026.07

  ISSN  1341321X

  　View Summary

  Practical Antimicrobial Therapeutic Drug Monitoring (PAT) for vancomycin using Bayesian estimation is recommended for calculating the area under the concentration–time curve (AUC). In 2025, PAT was updated from version 3 to version 4, but differences in AUC estimations between these versions have not been examined. This study aimed to compare AUC estimations from both versions in the same patients.We conducted a multicenter, retrospective, observational study involving adult patients who received vancomycin treatment between September 2020 and December 2023, who underwent two-point sampling for initial TDM. AUC was calculated using both versions in three phases: 0–24 h (AUC<inf>0–24</inf>), 24–48 h (AUC<inf>24–48</inf>), and at steady state (AUC<inf>ss</inf>).The sample included 894 cases. AUC values from versions 3 and 4 showed a high correlation (r = 0.947–0.964), but phase-related differences emerged. Version 4 yielded significantly lower AUC<inf>0–24</inf> and AUC<inf>24–48</inf> values (median: 420.7 μg h/mL vs 373.5 μg h/mL, p < 0.001; 398.9 μg h/mL vs 379.8 μg h/mL, p < 0.001), while AUC<inf>ss</inf> was significantly higher in version 4 (448.4 μg h/mL vs 498.2 μg h/mL, p < 0.001).Since differences in population pharmacokinetic models can affect estimation results, clinicians should be aware that AUC estimations may vary depending on the PAT version used, and the results should be interpreted with caution.

  • Access to Document (DOI)

• Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study

  Ishigo T., Suzuki A., Ibe Y., Fujii S., Fukudo M., Yoshida H., Tanaka H., Fujihara H., Yamaguchi F., Ebihara F., Maruyama T., Yagi Y., Hamada Y., Samura M., Nagumo F., Komatsu T., Tomizawa A., Takuma A., Chiba H., Nishi Y., Igarashi Y., Enoki Y., Matsumoto K.

  Journal of Antimicrobial Chemotherapy 81 ( 3 )  2026.03

  ISSN  03057453

  　View Summary

  Objectives To clarify the relationship between acute kidney injury (AKI) and vancomycin use in patients with renal impairment and to establish a risk score for AKI. Methods In this retrospective, multicentre, observational cohort study, trough and peak blood samples were collected from patients who initiated vancomycin therapy. The cumulative incidence of AKI within 14 days was compared among three groups classified according to renal function (estimated glomerular filtration rate ≥ 60, 30-59 and <30 mL/min/1.73 m²). The risk score and predicted probability of AKI incidence were calculated. AKI was defined in accordance with the Kidney Disease Improving Global Outcomes criteria. Results The incidence of AKI was 11.7% (99/847). No statistically significant difference was detected in the cumulative incidence of AKI among the three groups (P = 0.103). Cox proportional hazard analysis showed that the use of tazobactam/piperacillin [HR: 3.3, 95% CI (2.18-4.99), 2 points], vasopressors/inotropes [HR: 3.0, 95% CI (2.02-4.51), 2 points] and area under the concentration-time curve (AUC) on Day 2 [500-600 µg·h/mL: HR, 2.4, 95% CI (1.50-3.89), 1 point; >600 µg·h/mL: HR, 4.4, 95% CI (2.62-7.37), 3 points] were significantly related to the development of AKI. The predicted probabilities of AKI incidence were <5% (low-risk), 5% to <20% (moderate-risk), 20% to <40% (high-risk) and 40% to 67% (very high-risk), with total points of 0, 1-2, 3-4 and ≥5, respectively. Conclusions A risk prediction model was developed for AKI based on AUC exposure and concomitant medications, and no difference in AKI risk was observed across renal function categories.

  • Access to Document (DOI)

• Application of epithelial lining fluid drug concentrations to MICi-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia

  Yuki Mizukami, Mishu Takahashi, Kenta Suzuki, Shaoqing Duan, Shintaro Ikegami, Takuma Muraishi, Natsuki Satake, Yuko Okamoto, Yuki Igarashi, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto

  Journal of Infection and Chemotherapy 32 ( 1 ) 102889 2026.01

  Research paper (scientific journal), Corresponding author, Accepted,  ISSN  1341321X

  　View Summary

  Introduction: Nacubactam is a novel β-lactamase inhibitor with intrinsic antibacterial activity that shows therapeutic potential against carbapenemase-producing Enterobacterales when administered with β-lactam antibiotics. Pharmacokinetics/pharmacodynamics (PK/PD) analyses based on drug concentrations at the site of infection are recommended to better evaluate antibiotic efficacy. A new PD index, the instantaneous minimum inhibitory concentration (MIC<inf>i</inf>), which dynamically reflects the changing susceptibility of β-lactams during co-administration with β-lactamase inhibitors, has recently been proposed. This study aimed to assess the efficacy of cefepime combined with nacubactam in a murine model of pneumonia using MIC<inf>i</inf>-based PK/PD analysis in the lung epithelial lining fluid (ELF). Methods: In vitro pharmacodynamic testing using the checkerboard method was conducted with two β-lactamase-producing Klebsiella pneumoniae strains. In vivo PK and PD studies were performed in neutropenic mice using both β-lactamase-producing and non-producing strains. Drug concentrations in plasma and ELF were measured, and MIC<inf>i</inf>-based PK/PD analysis was conducted. Results: In vitro, the MIC of cefepime decreased in a concentration-dependent manner with increasing nacubactam. In the murine model of pneumonia, cefepime monotherapy resulted in bacterial changes of 0.12–4.30 log<inf>10</inf> CFU/lung, while the combination therapy reduced bacterial counts by −5.93 to −0.234 log<inf>10</inf> CFU/lung. The percentage of time that free cefepime concentrations exceeded MIC<inf>i</inf> (T > MIC<inf>i</inf>) was highly correlated with bacterial reduction. The target T > MIC<inf>i</inf> for maximal effect was estimated to be 29.3 %. Conclusions: These findings support the utility of MIC<inf>i</inf>-based PK/PD analysis for optimizing combination antibiotic therapy in pneumonia.

  • Access to Document (DOI)

• Practical dose ranges supporting target vancomycin exposure with AUC-guided dosing in overweight and obese patients: A multicentre retrospective study

  Endo A., Hanai Y., Namiki T., Hanawa K., Hashi H., Asakawa D., Yokoyama Y., Maruyama R., Tsujimura S., Igarashi Y., Enoki Y., Matsumoto K., Matsumoto K.

  British Journal of Clinical Pharmacology  2026

  ISSN  03065251

  　View Summary

  Aim: Evidence supporting area under the concentration–time curve (AUC)–guided vancomycin dosing in overweight and obese patients remains limited. This multicentre retrospective study aimed to identify pragmatic loading dose (LD) and maintenance dose (MD) ranges associated with target AUC attainment in this population. Methods: Patients aged ≥15 years with a body mass index (BMI) ≥ 25 kg/m² who received vancomycin for ≥3 days and had ≥2 trough concentration measurements were included from four Japanese hospitals (2012–2025). AUC<inf>0–24</inf> and steady-state AUC<inf>24</inf> (AUC<inf>ss</inf>) were estimated using Bayesian software. Multivariate logistic regression analyses identified factors associated with achieving target AUCs (AUC<inf>0–24</inf>: 400–500 μg·h/mL; AUC<inf>ss</inf>: 400–600 μg·h/mL). Results: Among 209 patients (median BMI 27.2 kg/m²), LD was independently associated with attainment of target AUC<inf>0–24</inf> (OR 1.08, 95% CI 1.02–1.15). An LD of approximately 20 mg/kg was associated with early target exposure. For maintenance therapy, estimated glomerular filtration rate (eGFR) and MD were independently associated with AUC<inf>ss</inf> attainment (OR 0.979, 95% CI 0.964–0.995, p = 0.008; OR 1.050, 95% CI 1.010–1.090, p = 0.018, respectively). Pragmatic interim MD ranges were approximately 9.2, 16.2 and 26.3 mg/kg/day for patients with eGFR<30, 30–60 and >60 mL/min/1.73 m², respectively. Conclusion: In this multicentre real-world cohort of overweight/obese adults, an LD around 20 mg/kg (ceiling 2 g) was associated with early AUC<inf>0–24</inf> target attainment. MD and renal function were independent predictors of AUC<inf>ss</inf>, informing interim renal-stratified MD ranges until TDM results become available. Early TDM remains essential given significant inter-individual variability.

  • Access to Document (DOI)

• PCV13/PPSV23 Co-vaccination versus PPSV23 Monotherapy for the Prevention of Pneumococcal Infections: A Systematic Review and Meta-analysis

  Matsumoto Y., Mihara T., Okamoto Y., Tsubouchi A., Ikegami S., Takahashi M., Nakabayashi K., Nishimoto N., Mizukami Y., Muraishi T., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

  Biological and Pharmaceutical Bulletin 49 ( 4 ) 666 - 682 2026

  ISSN  09186158

  　View Summary

  The 23-valent pneumococcal polysaccharide (PPSV23) and 13-valent pneumococcal conjugate (PCV13) vaccines are available for the prevention of infections caused by Streptococcus pneumoniae. This systematic review and meta-analysis evaluated the immunogenicity and safety of PPSV23 and PCV13 co-vaccination (PCV13/PPSV23) compared with PPSV23 monotherapy in adult populations. PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov were systematically searched for randomized controlled trials (RCTs) comparing PCV13/PPSV23 co-vaccination with PPSV23 monotherapy published until September 15, 2023. Immunogenicity was assessed using the geometric mean titer ratio (GMTR) of opsonophagocytic activity (OPA), which reflects bactericidal activity against each serotype. The safety outcomes included local and systemic adverse events. The risk ratios and 95% confidence intervals were calculated using the inverse variance-weighted method. The meta-analysis included 4 RCTs involving 2739 participants. The OPA GMTRs for 11 of the 13 evaluated serotypes were significantly higher in the PCV13/PPSV23 group than those in the PPSV23 group. The safety analysis showed no statistically significant differences in the incidence of adverse events between the 2 groups across all assessed outcomes. PCV13/PPSV23 showed significantly higher immunogenicity against the pneumococcal serotypes and maintained a safety profile comparable to that of PPSV23. These results support the potential utility of PCV13/PPSV23 as an effective strategy for preventing pneumococcal diseases in older adults.

  • Access to Document (DOI)

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• 腸球菌感染性心内膜炎に対するアンピシリン/セフトリアキソン併用療法とβラクタム系抗菌薬/アミノグリコシド系抗菌薬併用療法の比較

  杉本 唯衣, 佐々木 崚介, 富永 真由, 平井 柳佳, 三原 貴之, 岡本 侑子, 五十嵐 裕貴, 榎木裕紀, 田口和明, 松元一明

  [Domestic presentation]  医療薬学フォーラム2026／第34回クリニカルファーマシーシンポジウム, 

  2026.06

  , 

  Poster presentation

• 炎症性腸疾患を背景にもつClostridioidesdifficile 感染症に対する最適治療法の提案

  三原貴之, 五十嵐裕貴, 榎木 裕紀, 田口 和明, 松元 一明

  第100回日本感染症学会総会学術講演会／第74回日本化学療法学会総会合同学会, 

  2026.05

  , 

  Symposium, workshop panel (nominated)

• 診療情報データベースを用いたメトロニダゾール誘発中枢神経障害のリスク定量化

  髙田啓介, 今井俊吾, 佐村 優, 五十嵐裕貴, 榎木裕紀, 松元一明

  第100回日本感染症学会総会学術講演会／第74回日本化学療法学会総会合同学会, 

  2026.05

• 肺移行性の異なるレスピラトリーキノロンにおける肺上皮膜液中濃度に基づくPK/PD解析の有用性

  細井彩夏, 島田そら, 鈴木健太, 水上雄貴, 高橋実秀, 五十嵐裕貴, 榎木裕紀, 松元一明

  第100回日本感染症学会総会学術講演会／第74回日本化学療法学会総会合同学会, 

  2026.05

• PATversion3とversion4で推定したバンコマイシンAUCの比較

  鈴木絢子, 吉田博昭, 田中宏明, 石郷友之, 藤居 賢, 海老原文哉, 丸山拓実, 八木祐助, 浜田幸宏, 南雲史雄, 佐村 優, 小松敏彰, 冨澤 淳, 千葉博暁, 詫間章俊, 西 圭史, 五十嵐裕貴, 榎木裕紀, 松元一明

  第100回日本感染症学会総会学術講演会／第74回日本化学療法学会総会合同学会, 

  2026.05

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• HFIMを用いたCFPM/NACのヒステリシス解析による時差投 与戦略の探索

  2026.04

  -

  2027.03

  慶應義塾大学, 2026年度　学事振興資金（個人研究）, No Setting, Principal investigator

• 肺オルガノイドと送液灌流系を用いた抗菌薬PK/PD評価モデルの開発

  2026.04

  -

  2029.03

  Japan Society for the Promotion of Science (JSPS), Grants-in-Aid for Scientific Research, Grant in Aid for Early-Career Scientists, Principal investigator

• Mycobacterium abscessus complexのペニシリン結合タンパク質に対するβ-ラクタム系抗菌薬併用療法の結合特性評価

  2026.03

  -

  2027.03

  慶應義塾大学薬学部KP会, Naomi Hoshino Memorial Grant for Pharmaceutical Initiatives, Principal investigator

• MA-T技術を活用した新規消毒剤の開発研究

  2025.08

  -

  2026.04

  OTC Self-Medication Promotion Foundation, 調査・研究助成, Principal investigator

• 瞬間的MICとHFIMを用いた感染部位指向型PK/PD評価手法の構築

  2025.04

  -

  2027.03

  Japan Society for the Promotion of Science (JSPS), Grants-in-Aid for Scientific Research, Grant-in-Aid for Research Activity Start-up, Principal investigator

display all >>

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• 第17回日本化学療法学会東日本支部支部長賞（基礎）

  鈴木健太,島村莉奈,吉川万衣子,宇山杏奈,林侑孝,五十嵐裕貴,榎木裕紀,西村知泰,松元一明, 2026.01, 日本化学療法学会, Hollow Fiber Infection Modelを用いた肺MAC症に対する標準治療の有効性評価

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 第35回日本医療薬学会年会優秀演題賞

  石郷友之,鈴木絢子,藤居賢,伊部裕太,福土将秀,吉田博昭,田中宏明,海老原文哉,丸山拓実,八木祐助,佐村優,南雲史雄,小松敏彰,冨澤淳,詫間章俊,千葉博暁,五十嵐裕貴,榎木裕紀,浜田幸宏,西圭史,松元一明, 2025.11, 日本医療薬学会, 腎機能低下症例は2点採血でバンコマイシンのAUCを適切に調整することでAKIリスクを上昇させない

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 第8回フレッシャーズ・カンファランス優秀演題発表賞

  島村莉奈,西村知泰,吉川万衣子,三澤可奈,矢野大和,榎木裕紀,五十嵐裕貴,長谷川直樹,南宮湖,松元一明, 2025.06, 抗菌薬投与が引き起こすMycobacterium abscessusの細胞壁脂質とコロニー形態変化

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 日本化学療法学会Young Challenger Award（YCA）2025

  五十嵐裕貴, 2025.05, 日本化学療法学会, β-ラクタム薬/β-ラクタマーゼ阻害薬の併用療法におけるin vivo pharmacokinetics/pharmacodynamics評価方法の構築

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 第34回日本医療薬学会年会Postdoctoral award

  五十嵐裕貴, 2024.11, 日本医療薬学会, β-ラクタム薬/β-ラクタマーゼ阻害薬の併用療法におけるin vivo pharmacokinetics/pharmacodynamics評価方法の構築

  Type of Award： Award from Japanese society, conference, symposium, etc.

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• DRUG INFORMATION AND PHARMACODYNAMICS

  2026

• PRE-CLINICAL TRAINING IN PRESCRIPTION PROCESSING FOR HOSPITAL & COMMUNITY PHARMACY

  2026

• BACHELOR'S THESIS

  2026

• STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

  2026

• DISPENSING PHARMACY

  2026

display all >>

Memberships in Academic Societies 【 Display / hide 】

Memberships in Academic Societies 【 Display / hide 】

• Japanese Society of Hospital Pharmacists, 

  2026.02

  -

  Present

• Tokyo Metropolitan Society of Health System Pharmacists, 

  2026.02

  -

  Present

• 日本薬学会, 

  2025.11

  -

  Present

• The Japanese Society of Clinical Pharmacology and Therapeutics, 

  2025.01

  -

  Present

• The Japanese Society of Pharmaceutical Health Care and Sciences, 

  2021.02

  -

  Present

display all >>

Committee Experiences 【 Display / hide 】

Committee Experiences 【 Display / hide 】

• 2025.12

  -

  Present

  日本化学療法学会　評議員